Enter Your Search:
Results 1-2 (2)
Go to page number:
Select a Filter Below
BMC Clinical Pharmacology (1)
Critical Care (1)
Al Knawy, Bandar (1)
Al Knawy, Bandar A (1)
Al-Abdulkareem, Abdulmajeed (1)
AlJumah, Abdulrahman (1)
Arabi, Yaseen (1)
Arabi, Yaseen M (1)
Bardou, Marc (1)
Barkun, Alan N (1)
Brits, Riette (1)
Cherfan, Antoine J (1)
Hajeer, Ali (1)
Rishu, Asgar H (1)
Tamim, Hani M (1)
Tamimi, Waleed (1)
Year of Publication
Did you mean:
author:("Al knaw, Bandar A")
Etomidate and mortality in cirrhotic patients with septic shock
Cherfan, Antoine J
Tamim, Hani M
Rishu, Asgar H
Arabi, Yaseen M
BMC Clinical Pharmacology
Clinical effects and outcomes of a single dose etomidate prior to intubation in the intensive care setting is controversial. The aim of this study is to evaluate the association of a single dose effect of etomidate prior to intubation on the mortality of septic cirrhotic patients and the impact of the subsequent use of low dose hydrocortisone.
This is a nested-cohort study within a randomized double blind placebo controlled study evaluating the use of low dose hydrocortisone in cirrhotic septic patients. Cirrhotic septic patients ≥ 18 years were included in the study. Patients who received etomidate prior to intubation were compared to those who did not receive etomidate for all cause 28-day mortality as a primary outcome.
Sixty two intubated patients out of the 75 patients randomized in the initial trial were eligible for this study. Twenty three of the 62 intubated patients received etomidate dose prior to intubation. Etomidate use was not associated with all cause 28-day mortality or hospital mortality but was associated with significantly higher ICU mortality (91% vs. 64% for etomidate and controls groups, respectively; p = 0.02). Etomidate patients who received subsequent doses of hydrocortisone required lower doses of vasopressors and had more vasopressor-free days but no improvement in mortality.
In this group of septic cirrhotic patients with very high mortality, etomidate increased ICU mortality. Subsequent use of hydrocortisone appears to have no benefit beyond decreasing vasopressor requirements. The lowest mortality was observed in patients who did not receive etomidate but received hydrocortisone.
Pro/con debate: Octreotide has an important role in the treatment of gastrointestinal bleeding of unknown origin?
Barkun, Alan N
Whether it is the primary reason for admission or a complication of critical illness, upper gastrointestinal bleeding is commonly encountered in the intensive care unit. In this setting, in the absence of endoscopy, intensivists generally provide supportive care (transfusion of blood products) and acid suppression (such as proton pump inhibitors). More recently, octreotide (a somatostatin analogue) has been used in such patients. However, its precise role in patients with upper gastrointestinal bleeding is not necessarily clear and the drug is associated with significant costs. In this issue of Critical Care, two expert teams debate the merits of using octreotide in non-variceal upper gastrointestinal bleeding.
Results 1-2 (2)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
Canada Institute for Scientific and Technical Information
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.